Skip to main content

Relapsed/Refractory B-cell Malignancies

6
Pipeline Programs
5
Companies
6
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 5 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
2
IASO208 injectionPhase 11 trial
ZZSW-01 injectionPhase 11 trial
Active Trials
NCT07309900Recruiting12Est. Jun 2029
NCT07240974Recruiting6Est. Sep 2028
Legend Biotech
Legend BiotechNJ - Piscataway
2 programs
2
LVIVO-TaVec100 productPhase 11 trial
LVIVO-TaVec122 productPhase 11 trial
Active Trials
NCT07002112Recruiting30Est. Jun 2029
NCT07628582Not Yet Recruiting48Est. Sep 2030
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
TirabrutinibPhase 1Small Molecule1 trial
Active Trials
NCT02457559Completed29Est. Dec 2020
Ubix Therapeutics
Ubix TherapeuticsKorea - Seoul
1 program
1
UBX-303061Phase 11 trial
Active Trials
NCT06590961Recruiting94Est. Aug 2027
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
TirabrutinibPHASE_1Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Legend BiotechLVIVO-TaVec122 product
UNION therapeuticsIASO208 injection
UNION therapeuticsZZSW-01 injection
Legend BiotechLVIVO-TaVec100 product
Ubix TherapeuticsUBX-303061
Kite PharmaTirabrutinib

Clinical Trials (6)

Total enrollment: 219 patients across 6 trials

NCT07628582Legend BiotechLVIVO-TaVec122 product

A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

Start: Sep 2026Est. completion: Sep 203048 patients
Phase 1Not Yet Recruiting
NCT07309900UNION therapeuticsIASO208 injection

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

Start: Nov 2025Est. completion: Jun 202912 patients
Phase 1Recruiting
NCT07240974UNION therapeuticsZZSW-01 injection

Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies

Start: Oct 2025Est. completion: Sep 20286 patients
Phase 1Recruiting
NCT07002112Legend BiotechLVIVO-TaVec100 product

The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Start: May 2025Est. completion: Jun 202930 patients
Phase 1Recruiting
NCT06590961Ubix TherapeuticsUBX-303061

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Start: Feb 2025Est. completion: Aug 202794 patients
Phase 1Recruiting
NCT02457559Kite PharmaTirabrutinib

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Start: Sep 2015Est. completion: Dec 202029 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 219 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.